Register | Log in | FAQ      [?] 
Recent | Recommended | Search | Authors | Tags | Export

Group: XROWXR - library [901 articles]

Recent papers posted by members of the XROWXR group
  • Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Int Clin Psychopharmacol, Vol. 22, No. 2. (March 2007), pp. 107-115.
    by B Fantino, N Moore, H Verdoux, JP Auray
    posted to as depression by worx11 to the group XROWXR on 2007-10-18 17:22:13 as **
  • SSRIs versus other antidepressants for depressive disorder.
    Cochrane Database Syst Rev, No. 2. (2000)
    by JR Geddes, N Freemantle, J Mason, MP Eccles, J Boynton
    posted to as depression by worx11 to the group XROWXR on 2007-10-18 13:30:13 as **
  • WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs).
    Cochrane Database Syst Rev, No. 3. (2007)
    by C Barbui, M Hotopf, N Freemantle, J Boynton, R Churchill, MP Eccles, JR Geddes, R Hardy, G Lewis, JM Mason
    posted to as depression by worx11 to the group XROWXR on 2007-10-18 13:29:50 as **
  • WITHDRAWN: Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression.
    Cochrane Database Syst Rev, No. 3. (2007)
    by JR Geddes, N Freemantle, J Mason, MP Eccles, J Boynton
    posted to as depression by worx11 to the group XROWXR on 2007-10-18 13:29:29 as **
  • [Review of double-blind studies comparing SSRI and SNRI]
    Seishin Shinkeigaku Zasshi, Vol. 106, No. 10. (2004), pp. 1203-1217.
    by E Suzuki, S Maruta
    posted to as depression by worx11 to the group XROWXR on 2007-10-18 13:29:01 as **
  • An overview of SSRI and SNRI therapies for depression.
    Manag Care, Vol. 13, No. 6 Suppl Depression. (June 2004), pp. 25-33.
    by JB Weilburg
    posted to as depression by worx11 to the group XROWXR on 2007-10-18 13:28:33 as **
  • Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.
    J Clin Psychiatry, Vol. 67, No. 12. (December 2006), pp. 1836-1855.
    by HG Ruhé, J Huyser, JA Swinkels, AH Schene
    posted to as depression by worx11 to the group XROWXR on 2007-10-18 13:28:12 as ** along with 1 person and 2 groups vdbroekw Neuroscience Psychiatry
  • Management of diabetes in older adults.
    Am J Med Sci, Vol. 333, No. 1. (January 2007), pp. 35-47.
    by AA Rizvi
    posted to diabetes me senior_care_research by worx11 to the group XROWXR on 2007-10-10 14:50:46 as **
  • Improving quality of care for urban older people with diabetes mellitus and cardiovascular disease.
    J Am Geriatr Soc, Vol. 55, No. 10. (October 2007), pp. 1656-1662.
    posted to diabetes me senior_care_research by worx11 to the group XROWXR on 2007-10-10 14:50:19 as **
  • Better glycemic control in the hospital: beneficial and feasible.
    Cleve Clin J Med, Vol. 74, No. 2. (February 2007)
    by S Clement
    posted to diabetes hospital me by worx11 to the group XROWXR on 2007-10-10 14:48:56 as **
  • Hospital protocols for targeted glycemic control: Development, implementation, and models for cost justification.
    Am J Health Syst Pharm, Vol. 64, No. 10 Suppl 6. (15 May 2007)
    by MF Magee
    posted to diabetes hospital me by worx11 to the group XROWXR on 2007-10-10 14:48:25 as ** along with 2 people jyuh shamsha
  • Hyperglycemia management in the hospital setting.
    Am J Health Syst Pharm, Vol. 64, No. 10 Suppl 6. (15 May 2007)
    by E Hassan
    posted to diabetes hospital me by worx11 to the group XROWXR on 2007-10-10 14:48:01 as ** along with 2 people jyuh shamsha
  • Management of diabetes mellitus in hospitalized patients: efficiency and effectiveness of sliding-scale insulin therapy.
    Pharmacotherapy, Vol. 26, No. 10. (October 2006), pp. 1421-1432.
    by LK Golightly, MA Jones, DH Hamamura, NM Stolpman, MT McDermott
    posted to diabetes hospital me by worx11 to the group XROWXR on 2007-10-10 14:45:27 as ** along with 1 person scottd2104
  • An institutional process to improve inpatient glycemic control.
    Qual Manag Health Care, Vol. 16, No. 3. (p 2007), pp. 239-249.
    by LR Reynolds, AM Cook, DA Lewis, MC Colliver, SS Legg, NG Barnes, J Conigliaro, RP Lofgren
    posted to hospital diabetes me by worx11 to the group XROWXR on 2007-10-10 14:44:15 as **
  • Diabetes care in hospitalized noncritically ill patients: More evidence for clinical inertia and negative therapeutic momentum.
    J Hosp Med, Vol. 2, No. 4. (July 2007), pp. 203-211.
    by CB Cook, JC Castro, RE Schmidt, SM Gauthier, MD Whitaker, LR Roust, R Argueta, BP Hull, RS Zimmerman
    posted to diabetes hospital me by worx11 to the group XROWXR on 2007-10-10 14:43:45 as **
  • Treatment of hypoglycemia in hospitalized adults: a descriptive study.
    Diabetes Educ, Vol. 33, No. 4. (g 2007), pp. 709-715.
    by M Anthony
    posted to diabetes hospital me by worx11 to the group XROWXR on 2007-10-10 14:43:17 as **
  • Severe hypoglycemia in critically ill patients: Risk factors and outcomes*
    Crit Care Med (21 August 2007)
    by James S Krinsley, Aarti Grover
    posted to diabetes hospital me by worx11 to the group XROWXR on 2007-10-10 14:42:36 as ** along with 1 person pstrasma
  • RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes (RABBIT 2 Trial).
    Diabetes Care (18 May 2007)
    by Guillermo E E Umpierrez, Dawn Smiley, Ariel Zisman, Luz M M Prieto, Andres Palacio, Miguel Ceron, Alvaro Puig, Roberto Mejia
    posted to diabetes hospital me by worx11 to the group XROWXR on 2007-10-10 14:42:04 as ** along with 3 people jyuh scottd2104 shamsha
  • Chronically Critically Ill Patients: Health-Related Quality of Life and Resource Use After a Disease Management Intervention
    Am J Crit Care, Vol. 16, No. 5. (1 September 2007), pp. 447-457.
    by Sara L Douglas, Barbara J Daly, Carol G Kelley, Elizabeth O'Toole, Hugo Montenegro
    posted to diabetes me quality_of_life by worx11 to the group XROWXR on 2007-10-10 14:41:03 as ** along with 2 people suizan simdoc
  • Diabetes team consultation: Impact on length of stay of diabetic patients admitted to a short-stay unit.
    Diabetes Res Clin Pract, Vol. 78, No. 2. (November 2007), pp. 211-216.
    posted to diabetes me by worx11 to the group XROWXR on 2007-10-10 14:39:55 as **
  • Safety and efficacy of antiestrogens for prevention of breast cancer.
    Am J Health Syst Pharm, Vol. 57, No. 14. (15 July 2000)
    by P Reddy, MS Chow
    posted to ac chemoprevention serm by worx11 to the group XROWXR on 2007-10-04 20:23:53 as **
  • Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.
    Am J Ther, Vol. 13, No. 4. (g 2006), pp. 337-348.
    by T Bao, T Prowell, V Stearns
    posted to ac chemoprotective serm by worx11 to the group XROWXR on 2007-10-04 15:55:01 as **
  • Raloxifene examined for breast cancer prevention.
    Am J Health Syst Pharm, Vol. 64, No. 17. (1 September 2007)
    by D Young
    posted to ac chemoprotective serm by worx11 to the group XROWXR on 2007-10-04 15:34:54 as **
  • Challenges and recommendations for advancing the state-of-the-science of quality of life assessment in symptom management trials.
    Cancer, Vol. 110, No. 7. (20 August 2007), pp. 1621-1628.
    by David R R Buchanan, Ann M M O'mara, Joseph W W Kelaghan, Maria Sgambati, Worta McCaskill-Stevens, Lori Minasian
    posted to quality_of_life quality oncology bm by worx11 to the group XROWXR on 2007-09-21 17:19:50 as ** along with 1 person suizan
  • Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    Clin Ther, Vol. 27, No. 8. (August 2005), pp. 1295-1310.
    by E De Cock, J Hutton, P Canney, JJ Body, P Barrett-Lee, MP Neary, G Lewis
    posted to outcomes oncology cost-effectiveness bm by worx11 to the group XROWXR on 2007-09-20 20:23:29 as **
  • Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    Support Care Cancer, Vol. 13, No. 12. (December 2005), pp. 975-986.
    by E De Cock, J Hutton, P Canney, JJ Body, P Barrett-Lee, MP Neary, G Lewis
    posted to outcomes oncology cost-effectiveness bm by worx11 to the group XROWXR on 2007-09-20 20:21:31 as **
  • The Medicare Prescription Drug Improvement and Modernization Act and the delivery of cancer chemotherapy.
    Am J Health Syst Pharm, Vol. 64, No. 15 Suppl 10. (1 August 2007)
    by C Downs
    posted to oncology medicare_part_d medicare bm by worx11 to the group XROWXR on 2007-09-20 20:17:29 as **
  • Formulary issues at a pediatric hospital: experience at Children's National Medical Center.
    Hosp Formul, Vol. 26, No. 6. (June 1991), pp. 500-510.
    by GJ Cohen, SJ Allen
    posted to outcomes oncology formulary bm by worx11 to the group XROWXR on 2007-09-20 20:14:23 as **
  • Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    J Clin Oncol, Vol. 25, No. 18. (20 June 2007)
    by E Low,
    posted to outcomes oncology bm by worx11 to the group XROWXR on 2007-09-20 20:11:50 as **
  • European perspective on the costs and cost-effectiveness of cancer therapies.
    J Clin Oncol, Vol. 25, No. 2. (10 January 2007), pp. 191-195.
    by MF Drummond, AR Mason
    posted to outcomes oncology cost-effectiveness bm by worx11 to the group XROWXR on 2007-09-20 20:08:00 as **
  • Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.
    Br J Cancer, Vol. 89, No. 4. (18 August 2003), pp. 634-640.
    by A Gordois, P Scuffham, E Warren, S Ward
    posted to outcomes oncology cost-utility bm by worx11 to the group XROWXR on 2007-09-20 19:30:11 as **
  • Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
    Health Technol Assess, Vol. 8, No. 28. (July 2004)
    by K Dalziel, A Round, K Stein, R Garside, A Price
    posted to outcomes oncology cost-effectiveness bm by worx11 to the group XROWXR on 2007-09-20 19:27:43 as **
  • Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
    Pharmacoeconomics, Vol. 23, No. 5. (2005), pp. 515-526.
    by K Dalziel, A Round, R Garside, K Stein
    posted to outcomes oncology cost-effectiveness bm by worx11 to the group XROWXR on 2007-09-20 19:27:07 as **
  • Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Clin Ther, Vol. 26, No. 11. (November 2004), pp. 1924-1933.
    by E Warren, S Ward, A Gordois, P Scuffham
    posted to outcomes oncology cost-utility bm by worx11 to the group XROWXR on 2007-09-20 19:25:17 as **
  • Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Clin Ther, Vol. 26, No. 9. (September 2004), pp. 1546-1561.
    posted to outcomes oncology cost-utility budget_impact bm by worx11 to the group XROWXR on 2007-09-20 19:23:02 as **
  • Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
    Clin Drug Investig, Vol. 27, No. 2. (2007), pp. 85-93.
    posted to outcomes oncology cost-effectiveness bm by worx11 to the group XROWXR on 2007-09-20 19:21:12 as ** along with 1 person Terkko
  • Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Clin Breast Cancer, Vol. 7, No. 8. (June 2007), pp. 608-618.
    by TE Delea, J Karnon, O Sofrygin, SK Thomas, NL Papo, V Barghout
    posted to outcomes oncology cost-effectiveness bm by worx11 to the group XROWXR on 2007-09-20 19:18:02 as **
  • Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
    Pharmacoeconomics, Vol. 24, No. 3. (2006), pp. 237-250.
    by J Karnon, T Delea, SR Johnston, R Smith, J Brandman, J Sung, PE Goss
    posted to outcomes oncology cost-effectiveness bm by worx11 to the group XROWXR on 2007-09-20 19:16:06 as **
  • Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    Am J Clin Oncol, Vol. 26, No. 3. (June 2003), pp. 289-296.
    posted to oncology cost-utility bm by worx11 to the group XROWXR on 2007-09-20 19:15:12 as **
  • Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
    Breast, Vol. 16, No. 3. (June 2007), pp. 252-261.
    by C Skedgel, D Rayson, R Dewar, T Younis
    posted to outcomes oncology cost-utility bm by worx11 to the group XROWXR on 2007-09-20 19:02:57 as **
  • Reimbursement for cancer treatment: coverage of off-label drug indications.
    J Clin Oncol, Vol. 24, No. 19. (1 July 2006), pp. 3206-3208.
    by
    posted to oncology bm by worx11 to the group XROWXR on 2007-09-20 18:57:10 as **
  • Cost considerations in the management of cancer in the older patient.
    Oncology (Williston Park), Vol. 21, No. 7. (June 2007)
    by JM McKoy, KA Fitzner, BJ Edwards, M Alkhatib, CC Tigue, NJ Nonzee, CR Bolden, CL Bennett
    posted to outcomes oncology bm by worx11 to the group XROWXR on 2007-09-20 18:54:02 as **
  • Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate.
    Am J Manag Care, Vol. 13, No. 6 Pt 2. (June 2007), pp. 347-352.
    by DE Mager, ER Cox
    posted to bm benefit_design by worx11 to the group XROWXR on 2007-09-20 17:46:48 as **
  • Health plans' strategies for managing outpatient specialty pharmaceuticals.
    Health Aff (Millwood), Vol. 25, No. 5. (t 2006), pp. 1332-1339.
    by CD Mullins, DC Lavallee, FG Pradel, AR DeVries, N Caputo
    posted to bm benefit_design by worx11 to the group XROWXR on 2007-09-20 15:58:39 as **
  • Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors.
    Health Aff (Millwood), Vol. 26, No. 5. (t 2007)
    by P Neuman, MK Strollo, S Guterman, WH Rogers, A Li, AM Rodday, DG Safran
    posted to no-tag by worx11 to the group XROWXR on 2007-09-20 15:47:59 as **
  • Pharmacy benefit caps and the chronically ill.
    Health Aff (Millwood), Vol. 26, No. 5. (t 2007), pp. 1333-1344.
    posted to bm benefit_design by worx11 to the group XROWXR on 2007-09-20 15:45:58 as **
  • Major changes in benefit design: a plausible way to control costs?
    Find Brief, Vol. 9, No. 6. (November 2006), pp. 1-6.
    by C Demchak
    posted to bm benefit_design by worx11 to the group XROWXR on 2007-09-20 15:30:28 as **
  • Insurers' strategies for managing the use and cost of biopharmaceuticals.
    Health Aff (Millwood), Vol. 25, No. 5. (t 2006), pp. 1205-1217.
    by JC Robinson
    posted to bm benefit_design by worx11 to the group XROWXR on 2007-09-20 15:27:18 as **
  • Employer benefit design considerations for the era of biotech drugs.
    J Occup Environ Med, Vol. 49, No. 6. (June 2007), pp. 626-632.
    posted to bm benefit_design by worx11 to the group XROWXR on 2007-09-20 15:22:55 as **
  • Specialty pharmacy cost management strategies of private health care payers.
    J Manag Care Pharm, Vol. 12, No. 9. (c 2006), pp. 736-744.
    by D Stern, D Reissman
    posted to bm benefit_design by worx11 to the group XROWXR on 2007-09-20 15:19:38 as **
  • Note: You may cite this page as: http://www.citeulike.org/group/2840

    Result page: 1 2 3 4 5 6 7 8 9 10 Next RIS BibTeX
    CiteULike organises scholarly (or academic) papers or literature and provides bibliographic (which means it makes bibliographies) for universities and higher education establishments. It helps undergraduates and postgraduates. People studying for PhDs or in postdoctoral (postdoc) positions. The service is similar in scope to EndNote or RefWorks or any other reference manager like BibTeX, but it is a social bookmarking service for scientists and humanities researchers.